[Changes of immune and non-specific reactivity in patients with chronic suppurative obstructive bronchitis in comprehensive treatment with thymogen].
Litvinova. N V NV; Eremeev. V V VV; Abramova. Z P ZP; Kulikovskaia. N V NV; Gergert. V Ia VIa
Key Findings
- Thymogen increased T‑cell immunity indicators (E‑rosette formation, blast cell response to phytohemagglutinin, improved Tx/Tc ratio).
- Non‑specific immune responses improved (higher complement C3c, better NBT test results, increased natural killer activity).
- Patients receiving thymogen as part of a multi‑modal therapy showed greater clinical improvement compared to baseline.
Practical Outcomes
- For self‑directed health optimizers, thymogen appears to modestly boost both specific and innate immune functions, which could be useful for those seeking immune support during chronic infections or periods of immune stress. The study suggests a potential dosing regimen within a broader therapeutic protocol, but the evidence is limited to a small patient group, so further personal experimentation and safety monitoring are advised.
Summary
A small clinical trial (33 people) with chronic bronchial infection showed that adding the peptide thymogen to a broader treatment plan helped normalize several immune markers, like T‑cell activity and natural killer cell function, and led to better overall clinical outcomes.
Abstract
A total of 33 patients with chronic pyoobstructive bronchitis with immunological disorders (of T-cell and other links) and nonspecific responsiveness. The use of thymogen in multi-modality treatment contributed to normalization of T-cell immunity (increases in E-rosette formation, responses of blast cell transformation to phytohemagglutinin, Tx/Tc ratio), as well as nonspecific responsiveness parameters (C3c, NBT-test, natural killers), resulting in higher clinical efficacy.
Study Information
pubmed
1994